Welcome
Dear Colleague:
The National Institutes of Health is pleased to invite you to our meeting on the Evolution of Pulmonary Hypertension: Emerging Diseases and Novel Therapeutics, December 7-8, 2006, in Bethesda, Maryland.
This conference will bring together leading thinkers in the field to review current understanding of the pathobiology, pathogenesis, and therapy of pulmonary hypertension (PH). Presentations include the following topics:
- History of PH, focusing on development of current therapies and the role of combination therapy;
- Pathobiology of pulmonary hypertension and right heart failure, highlighting the role of inflammatory mediators, angiogenesis, and genetic susceptibility;
- Emerging diseases associated with pulmonary hypertension such as sickle cell disease, other hemolytic disorders, HIV, and respiratory disorders such as chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis;
- Potential novel therapies, including antioxidants, nitric oxide donors, vasodilators with pleotrophic effects, and antiproliferative agents.
Our goals for this conference are threefold: to provide a forum to present new concepts in basic, translational, and clinical pulmonary hypertension research; to promote scientific exchange of ideas; and, ultimately, to foster research collaboration.
We are grateful for the generous funding of this meeting by the National Heart, Lung, and Blood Institute; the National Institutes of Health’s Office of Rare Diseases, Office of the Director; Critical Care Medicine Department, Clinical Center; and the Clinical Center Bench-to-Bedside Awards.
We look forward to welcoming you to Bethesda in December.
Sincerely,
Steering Committee
Mark T. Gladwin, MD
National Heart, Lung and Blood Institute, NIH, DHHS
Roberto Machado, MD
National Heart, Lung and Blood Institute, NIH, DHHS
Robyn Barst, MD
Columbia University Medical Center
Lewis Rubin, MD
University of California, San Diego School of Medicine
David Badesch, MD
University of Colorado Health Sciences Center
Augustine Choi, MD
University of Pittsburgh School of Medicine
Elizabeth Nabel, MD
National Heart, Lung, and Blood Institute, NIH, DHHS
This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education through the Joint sponsorship of Columbia University Medical Center, University of California, San Diego School of Medicine, University of Colorado Health Sciences Center, and University of Pittsburgh School of Medicine. The National Institutes of Health/Foundation for Advanced Education in the Sciences (NIH/FAES) is accredited by the ACCME to provide continuing medical education for physicians.
The NIH/FAES designates this educational activity for a maximum of 13 AMA PRA Category 1 Credits.™ Physicians should only claim credit commensurate with the extent of their participation in the activity.
On-line report of attendance and evaluation
